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Placement of intravascular stents that can reach adult size in infants and smaller children
has been limited by the large profile and poor flexibility of currently available stents. In
vitro and in vivo testing of the Genesis stent was performed to evaluate crimpability,
predeployment flexibility, and radial strength. Comparisons were made to the Palmaz
iliac and IntraStent (IS) LD stents. Nine physicians placed 30 Genesis stents in swine
pulmonary and systemic arteries to evaluate stent deliverability/crimpability. Two swine
were recovered and underwent a second catheterization 8 weeks later, where the stents
(n  8) were reexpanded to maximal size. Angiographic and intravascular ultrasound
(IVUS) assessments were performed. In vitro testing revealed the Genesis stent to have
superior crimpability, flexibility, and comparable radial strength to the Palmaz iliac stent,
and superior crimpability and radial strength and comparable flexibility to the IS LD
series. During in vivo testing, the physicians graded the Genesis stent superior to the
Palmaz stent regarding crimpability and deliverability, and superior to the IS LD stent in
regard to crimpability, and comparable to or superior in deliverability. In the chronic
animals, the Genesis stent was expanded up to maximal diameter 8 weeks following
implantation. Angiographic and IVUS revealed no fractures no in-stent restenosis. The
Genesis stent can be easily delivered through smaller sheaths, which will facilitate their
use in infants and smaller children with vascular stenosis. Cathet Cardiovasc Intervent
2003;59:406–414. © 2003 Wiley-Liss, Inc.
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INTRODUCTION
Use of intravascular stents for treatment of vascular
obstructions in congenital heart disease was first intro-
duced by Mullins et al. [1] in 1988. Since then, stents
have been used to treat pulmonary artery and systemic
venous obstructions [2–4] and more recently systemic
arterial obstructions [5–7]. Due to rigidity of the stent
and the sheath size required for delivery, use of presently
available stents that can be dilated to adult size is tech-
nically very difficult in infants and smaller children.
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Renal stents, which can be delivered through smaller
sheaths and have increased predeployment trackability,
are technically easier to use in infants and smaller chil-
dren. Unfortunately, these stents cannot be dilated to
adult size and frequently require surgical removal and/or
patch augmentation of the blood vessel when the child
grows. In this report, we present in vitro and in vivo
experience with the Genesis stent (Cordis, Warren, NJ),
a new low-profile flexible stent that can be expanded
from infant to adult size.
MATERIALS AND METHODS
The Genesis stent was initially developed for the treat-
ment of biliary stenosis. The stent underwent further
modifications to meet four criteria: improved predeploy-
ment flexibility; ability to be dilated from 5 to 20 mm in
diameter; deliverability through a small (6–7 Fr) sheath;
and comparable radial strength to the Palmaz iliac series
stents at all diameters. Testing evaluated predeployment
crimpability, flexibility, deliverability, radial strength,
and stent shortening characteristics. Both premounted
and unmounted stents were tested.
In Vitro Testing
Stent design. The Genesis stent is made of stainless
steel and has a closed-cell configuration. In contrast to
the Palmaz stent (Johnson and Johnson, Sommerville,
NJ), also having a closed-cell design, sigma hinges have
been interpositioned between each cell (Fig. 1). The
Genesis stent will be available in 19, 25, 29, 39, and 49
mm preexpansion lengths. Table I compares the general
characteristics between the Genesis, Palmaz, and IS LD
stent series.
Crimpability. The Genesis, Palmaz, and IntraStent
double-strut LD (IS LD; EV3, Plymouth, MN) stent
series were hand-crimped on 5–8 mm OptaPro (Cordis)
balloon angioplasty catheters. The stent/balloon catheter
was advanced through 6, 7, and 8 Fr sheaths. The small-
est sheath that allowed easy delivery of the stent was
recorded. The sheaths tested were Brite Tip (Cordis) and
Flexor (Cook, Bloomington, IN) sheaths. The minimal
crimp diameter was measured for Palmaz and Genesis
stents, respectively.
Flexibility. Predeployment flexibility of the Genesis
stent was measured by determining the amount of force
(in pounds) required to flex the stent. Similar testing was
performed for the Palmaz iliac and IS LD stents. Testing
was performed using a three-point bend technique on the
stent alone. The test is an adaptation of American Society
for Testing and Materials (ASTM) D790. This test is
designed to evaluate the flexibility for any material and
was adapted for testing the stents. In the ASTM test, the
distance between supports is maintained at approxi-
mately 1. In the adaptation for testing stents, the support
is the length of the stent, allowing the ability to test stents
under 1  ( 25 mm) in length.
To perform the test, the internal space of the stent is
filled by finger crimping the stent onto 0.060 polyeth-
ylene tubing. This prevents the stent from buckling and
hinging on a given point. The stent, crimped onto the
0.060 tubing, is placed in the V-block. The load, which
is measured in pounds of force, is focused on the mid-
point of the stent. The force is applied using a cylindrical
mandrel with a 0.5 diameter. The load is continuously
monitored and values are determined at given displace-
ments. Comparisons between each stent type were made
at similar lengths (i.e., a 16 mm IS LD was compared to
an 18 mm Palmaz and Genesis 19 mm stent). The results
were used to compare the flexibility between each stent
series of similar length. Finally, to normalize the loads to
the stent length, a moment is calculated. The moment is
determined using the formula M  P(L/4), where P is the
load and L is the length of the stent.
Radial strength. The Genesis, Palmaz, and IS LD
stents underwent a series of radial strength testing at 10,
12, and 15 mm expanded diameters. Radial testing was
performed within a latex tube. The latex tubing, which
has an internal diameter that represents the target nomi-
nal expansion diameter (i.e., 10, 12, 15 mm), was cut
slightly longer than the stent. Expansion of each stent
was performed to balloon-rated burst pressure, with the
stents becoming imbedded within the latex tubing.
The balloon was removed, and special mandrels,
which have an outer diameter that corresponded to the
latex tubing internal diameter, were carefully positioned
onto the ends of the tubing to within 0.5 mm of the stent
ends. The mandrel/tube/stent assembly was inserted into
the radial strength testing fixture. The fixture consists of
a clear cylindrical lexan chamber with two tightly fitted
end caps. The chamber was slowly pressurized such that
the latex tubing begins to compress uniformly the stent
radially along its length. Within the stent, the pressure
remains at atmospheric level, and gradually a pressure
differential develops between the outside and inside of
the stent. The test was concluded at the collapse or failure
of the stent. The peak pressure recorded just prior to stent
failure was considered the maximal radial strength.
Stent shortening. Three Genesis, Palmaz, and IS LD
stents were serially dilated on 10, 12, 14, 15, and 18 mm
balloon catheters. The length of each stent was measured
at 12, 15, and 18 mm diameter, respectively, to assess
amount of stent shortening with expansion. The mean
percent foreshortening was calculated for each stent se-
ries and comparisons were made.
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In Vivo Testing Performed Only on Genesis Stent
Acute phase. This phase of the study tested stent
crimpability, deliverability, and the ability to retrieve a
preexpanded Genesis stent back into the sheath. Nine
physicians, with a combined experience of over 60 years
in stent placement in patients with congenital heart dis-
ease, participated in this part of the study. A total of 22
Genesis stents were placed in swine pulmonary arteries,
ascending and descending aorta, and the inferior vena
cava. Both premounted and unmounted 19/29/39 mm
Genesis stents were advanced on Cordis OptaLP and
OptaPro angioplasty catheters ranging from 5 to 14 mm
Fig. 1. A: An expanded Genesis stent is shown. The sigma hinges are interposed between each
cell. B shows the flexibility of the Genesis stent hand-crimped on a Cordis PowerFlex balloon
catheter. [Color figure can be viewed in the online issue, which is available at www.interscience.
wiley.com].
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in diameter through 6–8 Fr Brite tip sheaths. The method
of nesting unmounted Genesis stents on the balloon cath-
eters went as follows. The physician hand-crimped the
Genesis stent onto the balloon catheter. Prior to advance-
ment of the stent/balloon catheter into the sheath, the
balloon was partially inflated to 0.7 atm. This caused
partial expansion of the balloon ends, thereby fixing the
stent onto the balloon catheter (Fig. 2). The physicians
then graded these characteristics of the Genesis stent as
superior, comparable, or inferior in comparison to their
previous experience with Palmaz and IS LD stents.
Chronic phase. Two swine were used for the chronic
phase of the study, which evaluated stent expandability at
late redilation, shortening characteristics at larger diam-
eters, and in vivo stent/vessel wall interactions in regard
to neointimal buildup or endothelialization characteris-
tics. The stents were delivered into pulmonary arteries,
systemic arteries, and the superior vena cava. The swine
were recovered from the procedure and 8 weeks later
were brought back to the animal laboratory where the
stents were redilated to 18 and 20 mm diameter. Angiog-
raphy and intravascular ultrasound (IVUS) imaging were
performed prior to and following redilation. Following
explantation, the stents were analyzed grossly and fluo-
roscopically for final dimension, length, and fractures.
RESULTS
In Vitro Testing
Crimpability. Though the Genesis stent is 42%
thicker than its Palmaz counterpart, the minimal crimp
diameter of the Genesis stent is 30% less than that of the
Palmaz stent (Table I). This allows the Genesis stent to
be delivered through sheaths 1–2 Fr sizes smaller than
TABLE I. General Characteristics Between the Palmaz, Genesis, and IS LD Stents
Genesis 19/29/39 Palmaz P188/308 IS LD 16/26
Nominal expansion sizes 5–20 mm 7–18 mm 7–20 mm
Final wall thickness 0.0095 0.0055 0.0076
Minimal crimp diameter 0.066 0.093
Del Sh on 5–7 mm catheter 6 Fr 8 Fr 8 Fr
Del Sh on 8–12 mm catheter 7 Fr 9 Fr 9 Fr
Del Sh on 14–16 mm catheter 8 Fr 10 Fr 10 Fr
Del Sh, Delivery sheath
Fig. 2. Photograph of a hand-crimped Genesis stent on a Cordis OptaPro balloon catheter.
After crimping the stent onto the balloon catheter, the balloon catheter was carefully inflated to
0.5–0.7 atm pressure. This caused the ends of the balloon catheter to expand slightly, thereby
nesting the stent onto the balloon catheter. [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com].
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those required for delivery of the Palmaz iliac or IS LD
stent series when crimped on comparable balloon cathe-
ters. Due to the open-cell configuration of the IS LD
stent, a minimal crimp diameter was not able to be
obtained. In order to calculate a minimal crimp diameter,
the stent has to be able to be uniformly crimped through-
out its entire length. With the open-cell configuration of
the IS LD stent, uniform compression of the stent was
unable to be achieved. Table I compares the minimal
sheath sizes required for delivery of the Genesis, Palmaz,
and IS LD stents on Cordis OptaPro balloon angioplasty
catheters. For a given balloon catheter, unmounted Gen-
esis stents were able to be advanced easily through sheath
sizes, which were 1–2 Fr sizes smaller than either the
Palmaz or the IS LD stents.
Flexibility. Results of predeployment stent flexibility
in comparison to the Palmaz and IS LD stents is depicted
in Figure 3. The measurement is in pounds required to
flex the stent. The IS LD and Genesis stents have similar
preexpansion flexibility profiles, with the IS LD being
slightly superior to the Genesis series. Both were con-
siderably more flexible than the Palmaz series, measuring
at least four times more flexible than the Palmaz stent.
Radial strength. The Genesis 19/29, Palmaz 308, and
IS LD 16/26 stent series underwent radial strength testing
following dilation to 10, 12, and 15 mm in diameter. The
Genesis stent demonstrated radial strength equal to or
better than the Palmaz and nearly twice that of the IS LD
stent at all diameters (Fig. 4).
In vitro stent shortening. Minimal stent shortening
( 5%) was observed between all stents at 10 mm. At 15
mm, the P308 stents shortened 25%, the Genesis stent
shortened 16%, and the IS LD shortened 6%. At 18 mm
final diameter, the Palmaz P308 shortened nearly 45%.
The Genesis series shortened 34% from initial length of
39 mm and 20% from initial length of 19 mm. The IS LD
shortened 23 and 34% from initial lengths of 26 and 16
mm, respectively.
Acute-Phase In Vivo Testing
Flexibility/deliverability. All stents were successfully
delivered to their desired location. In one case, a pre-
mounted Genesis stent on a 5  2 cm OptaPro balloon
angioplasty catheter was successfully advanced through
the strut of a previously placed stent and expanded in a
branch vessel without a long sheath. In assessing the
Genesis predeployment flexibility, all nine operators
graded the Genesis stent superior in comparison to the
Palmaz iliac stent series. Of the six physicians who had
experience with the IS LD stent, five felt the Genesis
stent had superior flexibility and one graded the Genesis
comparable to the IS LD stent.
Crimpability. Regarding stent crimpability, our in
vivo experience correlated with our in vitro testing. All
physicians felt the Genesis stent had superior crimpabil-
ity characteristics to both the Palmaz iliac and IS LD
series stents. This improved crimpability also allowed
both premounted and unmounted stents, loaded on 5–12
mm Cordis OptaPro balloon catheters, to be pulled back
into a 7 Fr sheath prior to deployment without causing
stent dislodgment off the balloon catheter. The maneuver
of retracting the stent/balloon catheter back into the
sheath was performed with the sheath in the main pul-
monary artery (MPA) and stent/balloon catheter being
retracted back either from the distal right pulmonary
artery (RPA) or from the left pulmonary artery (LPA).
Fig. 3. Results of preexpansion flexibility testing of the Gene-
sis, Palmaz, and IS LD stents are presented. The graph delin-
eates the comparisons between each stent. The stent type is
depicted on the x-axis, and the amount of force (in pounds)
required to flex the stent is depicted on the y-axis.
Fig. 4. Radial strength comparison between the Genesis 19/
29, Palmaz 308, and IS LD 16/26 series stents is shown in this
graph. The x-axis denotes the final diameter tested. The y-axis
represents the amount of force per square inch required to
compromise stent lumen. The Genesis series has comparable
radial strength to the Palmaz series and approximately twice
the radial strength to the IS LD series at all diameters.
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Chronic-Phase In Vivo Testing
A total of eight stents were placed in the pulmonary
arteries (n  3), superior vena cava (n  1), and de-
scending aorta (n  4) in two swine. The stents were
initially deployed on 10 (n  2), 12 (n  5), and 14 (n 
1) mm balloon catheters. Depending on native vessel
size, five stents were redilated to 18 mm, and three
redilated to 20 mm diameter. The amount of stent short-
ening between acute (in vitro) and late (in vivo) redila-
tion of the Genesis 19/29 mm stents is depicted in Figure
5. There was a decrease of 11–12% in the amount of
shortening observed following late dilation in chronic
animals compared to the degree of shortening observed
at acute dilation. This appears to be due to straightening
of the sigma hinges associated with serial dilation within
the vessel wall (Fig. 6). Angiography and IVUS imaging
noted no significant neointimal buildup, intrastent throm-
bus or plaque, or stent fractures. There was no evidence
of vascular dissection, tear, or vessel injury observed at
the ends of the stents following redilation. At explanta-
tion, all stents appeared uniformly dilated.
DISCUSSION
This study demonstrates the advantageous properties
of the new Genesis stent and its potential use in infants
and smaller children with congenital heart disease. Fur-
thermore, we demonstrated the feasibility of redilating
the Genesis stent, to maximal diameter, at a later time.
Reexpansion of the Palmaz iliac stent series can be
performed years later, eventually reaching diameters ap-
propriate for adult-size patients [8]. Unfortunately, due to
the large sheath size required for delivery and the rigid
predeployment configuration of the Palmaz iliac series
stent, placement of these stents in infants and smaller
children can be technically difficult. The large stent size
has limited the interventionist’s options and, in some
cases, has led to placement of smaller renal/coronary
series stents in these patients. Use of smaller stents limits
expansion capabilities and will necessitate future surgical
interventions [9,10]. The Genesis stent series, with its
low profile and flexibility, will make it technically easier
for the interventionist to deliver a stent capable of reach-
ing adult size in infants, children, and adults with con-
genital heart disease.
Deliverability
The Genesis stents can easily be advanced through
sheath sizes that are 1–2 Fr smaller than those required
for iliac or other large-diameter stents currently avail-
able. Though recent innovative modifications to delivery
techniques have been devised to allow the Palmaz iliac
series stents to be preloaded and advanced in a 7 Fr
sheath, this technique requires the distal part of the
sheath to be predilated, thus allowing enough room for
the balloon/stent to fit through the sheath. This increases
the outer diameter of the sheath to be greater than 7 Fr.
Furthermore, in 15% of the cases, this technique has been
associated with perforations of the balloon catheter prior
to deployment of the stent [11]. Delivery using this
technique can also be cumbersome in infants and smaller
children, as the balloon, stent, and sheath have to be
advanced over the wire as a unit. We feel the increased
crimpability of the Genesis stent, and therefore lower
profile, is due in part to the hinges being interpositioned
between each cell.
Delivery of the Genesis stent through kink-resistant
flexor/guiding sheaths (Cook Flexor/Cordis Brite tip
sheaths) decreases the technical complexity of stent de-
livery in infants and smaller children. This technique
should not be associated with increased risk of balloon
perforation, as the balloon/stent is not forcibly introduced
into an undersized sheath. Furthermore, the improved
trackability of the stent will decrease the likelihood of
losing sheath position or encountering stent dislodgment
when crossing a stenotic segment. We feel that the stent’s
improved crimpability, combined with the nesting tech-
nique used, allowed for the operator to retract the stent/
balloon catheter back into the sheath without stent dis-
lodgment. Another technique to seat the stent onto the
balloon catheter is called cold nesting. The stent is hand-
crimped onto the balloon catheter in the usual fashion. A
small steel tube, whose internal diameter matches that of
the internal diameter of the delivery sheath, is advanced
over the stent/balloon catheter. The balloon is maximally
inflated inside the steel tube. The balloon is then deflated
to 0–0.2 atm pressure, with the steel tube removed. The
stent is then advanced in the usual fashion through the
sheath, now being nested on the balloon catheter. In the
premounted version of the stents, the interventionist will
Fig. 5. In vitro vs. in vivo (8-week) dilation of the Genesis 19/29
stent at 18 mm diameter. There is an 11–12% decrease in the
amount of foreshortening in the stents progressively dilated in
vivo vs. in vitro dilation.
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Fig. 6. Relative lengthening of the sigma hinges observed with
in vivo dilation. A is an expanded Genesis stent. The sigma
hinges, depicted by a star, remain relatively foreshortened. In
contrast, B is an X-ray image of a Genesis stent dilated in a
swine pulmonary artery. Further lengthening of the sigma
hinges can be seen, represented by two stars. Relative length-
ening of the sigma hinges accounts for the decreased fore-
shortening observed with in vivo dilation depicted in Figure 5.
[Color figure can be viewed in the online issue, which is avail-
able at www.interscience.wiley.com].
be able to launch the stent from a sheath placed proximal
to the stenosis [12]. Although this maneuver was suc-
cessfully performed with both mounted and unmounted
stents, the mounted stents offer an added measure of
safety, which is demonstrated in Figure 7. A premounted
Genesis stent is observed loaded on a Cordis OptaPro
balloon catheter. Protrusion of balloon material through
the struts of the stent increases the amount of friction
between the stent and the catheter. This decreases the risk
of stent dislodgment when retracting the stent back into
the sheath or repositioning the stent/balloon prior to
deployment. Using premounted stents, or the techniques
of nesting the stent onto the balloon catheter described,
the operator would no longer be required to cross the area
of stenosis with a sheath prior to stent deployment. The
authors, however, feel that placement of the sheath across
the stenotic region, when possible, remains the safest
method for deploying intravascular stents.
Radial Strength
The Genesis stent has superior radial strength at all
diameters in comparison to the Palmaz and IS LD stents.
Concerns have been noted with stent recoil of the IS LD
stent when expanded above 12 mm in diameter [13]. In
the authors’ experience, stent recoil with the IS LD stent
has been observed following treatment of baffle obstruc-
tions in a postoperative Mustard patient (W.H.), an ob-
structed lateral tunnel in a Fontan patient (J.V.), coarc-
tation of the aorta (Z.A., T.F., J.V., C.M.), and proximal
left pulmonary artery stenosis (T.F., C.M.). In each case,
balloon redilation of the stent, or placement of a second,
closed-cell stent within the previously placed IS LD
stent, was required. Concerns for stent recoil with the IS
LD version is supported by the dramatic decrease in
radial strength observed when expanded larger than 12
mm in diameter. Stent recoil has not been observed with
Palmaz stents. We anticipate, due to similar radial
strength characteristics to the Palmaz stent, the Genesis
stent will not be susceptible to stent recoil. This may be
due in part to the closed-cell design of the Genesis and
Palmaz stents in contrast to the open-cell design of the IS
LD series.
Stent Shortening
An 11–12% decrease in the amount of stent shortening
was observed with in vivo dilation of the Genesis stent in
Fig. 7. A photograph of a premounted Genesis stent loaded on a Cordis balloon catheter. The
premounted stent shows balloon material protruding between the struts of the stent. The
premounted stent will have increased stent/balloon interface, thereby decreasing the likelihood
of encountering stent dislodgment during deployment. [Color figure can be viewed in the online
issue, which is available at www.interscience.wiley.com].
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comparison to in vitro dilation. Though this phenomenon
is due to sigma hinge straightening, which was observed
with in vivo dilation, the reason for the relative mainte-
nance of stent length may be twofold. First, the stent
becomes imbedded within the vessel wall. The vessel
wall may decrease the amount of axial foreshortening of
the stent with serial dilation. The second relates to bal-
loon inflation dynamics. With the stent expanded on the
balloon catheter outside of the body, the balloon tends to
inflate outside the ends of the stent, spreading inward
toward the center. The balloon catheter can compress the
ends of the stent during inflation, exacerbating stent
shortening. This was observed even with serial dilation
of the stent with progressively larger balloon catheters.
Conversely, when expanded within the confines of a
vessel, though initial balloon expansion still occurred on
the outside, there appeared to be more uniform expansion
of the balloon, thereby decreasing the amount of axial
compression on the stent. We feel these are the most
likely reasons for the decrease in the amount of stent
shortening observed with in vivo dilation of the Genesis
stent.
Study Limitations
This study is limited to observations from in vitro and
in vivo experimental testing in the swine model. Further-
more, the model involved normal vessels, i.e., without
stenosis. Though the applications should apply to hu-
mans, testing of delivery and other characteristics of the
stent was not performed specifically in human subjects.
The in vivo physician comparisons of the deliverability
and crimpability characteristics of the Genesis, Palmaz,
and IS LD stents were subjective, with only Genesis
stents being used for this portion of the study. Therefore,
physician bias may have been introduced in this part of
the study.
The Genesis stent offers a promising new alternative
to the stents currently available for use in treatment of
vascular obstructions in congenital heart disease. With
improved deliverability and expandability of the Genesis
stent, an interventionist will be able to deliver stents
reliably in infants and smaller children that can be ex-
panded to adult size over time.
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